Background: In Australia in June 2001, a unique pneumococcal vaccine schedule commenced for Indigenous infants; seven-valent pneumococcal conjugate vaccine (7PCV) given at 2, 4, and 6 months of age and 23-valent pneumococcal polysaccharide vaccine (23PPV) at 18 months of age. This study presents carriage serotypes following this schedule.
Conclusion:
Pneumococcal carriage remains high (~80%) in this vaccinated population. Uptake of both pneumococcal vaccines increased, and carriage was reduced between 2003 and 2005. Predominant serotypes in combined years were 16F, 19A, 11A, 6C and 23B. Antimicrobial nonsusceptibility was detected in these and 17 additional serotypes. Shifts in serotype-specific carriage suggest a need more research to clarify the association between pneumococcal vaccination and carriage at the serotype level.
Background
Australian Aboriginal children in remote communities experience high rates of many infectious diseases [1, 2] , particularly pneumococcal disease. [3] Concern about antibiotic resistance is used as an argument against greater use of antibiotics. Recent reports describe escalating rates of disease caused by pneumococcal serotypes not included in currently licensed pneumococcal conjugate vaccine (7PCV), [3, 4] including an increasing proportion of isolates having antibiotic resistance. [5] [6] [7] Serotype 19A is of particular interest in Australia [3] and internationally. [8] More recent data suggests 6C as a new and emerging replacement serotype, and that 7PCV is crossprotective for 6A. Prior to 7PCV introduction in 2001, [9] pneumococcal carriage in Indigenous infants was around 80% and approximately 60% were 7PCV serotypes (unpublished data from 3 of the communities also in these surveys). In 2003 and 2005 we conducted wider geographic surveillance of pneumococcal carriage.
Methods

Vaccine schedule
From July 2001 7PCV was recommended and funded for Australian Aboriginal and other high-risk infants at 2, 4 and 6 months of age. In the Northern Territory and in South Australia, 23-valent pneumococcal polysaccharide vaccine (23PPV) was recommended as a booster dose for Aboriginal children at 18 months of age. [9] Children less than 2 years of age were offered catch-up 7PCV.
Study setting and participant eligibility criteria
Participating communities were in four regions of South Australia and the Northern Territory. Children were eligible if they were Aboriginal, 0 to 6 years of age, resident in a participating community, and if their parents or caregiver provided written consent.
Swab collection, antibiotic use and vaccination history Nasal secretions were collected using swabs or nose blowing into a tissue as previously described. [10, 11] Pneumococcal vaccination dates and antibiotics prescribed in the 5 weeks prior to swab collection were obtained from the NT childhood immunization register and participant medical records.
Microbiological analysis
Nasal secretions were transported, stored and processed as previously described. [10] Pneumococci were identified and one or more colonies (if morphologically distinct) selected for serotyping with antisera from the Statens Serum Institute (Denmark). Antimicrobial susceptibility was determined by disc diffusion [12] and Etest (AB Biodisk, Sweden). We performed PCR for the wciN gene. [13] Statistical analysis Confidence intervals (CI, 95%) and risk differences (RD, with 95% CI) were calculated where appropriate. Stata version 10 was used for all data analysis [14] Ethical Approval and Funding 
Results
Participant characteristics
Nasal secretions were collected from 902 children in 29 communities in 2003 and from 818 children in 17 communities in 2005 (Table 1) . Nasal swabs comprised 94% specimens. Mean age was 30 months. 83 were less than 6 months of age.
Vaccine uptake
In 2003 87% children had received at least 2 doses of 7PCV (Table 2 ). In 2005, this figure was 96% (Risk Difference = 9% [95% Confidence Interval 7, 12] ). The proportion of children receiving a full primary 7PCV plus booster , and 11A (6.5%) and 6C (6%) (see Figure 1 ).
Non-vaccinated children
In 2003 and 2005, carriage in 169 non-vaccinated children (no 7PCV or 23PPV) was 74% and 70% respectively; carriage of 7PCV types was 9% and 7%, 23PPV-non-7PCV types was 19% and 24%. Predominant serotypes were 16F(10%) and 19A(9%) followed by 6% each of 11A, 6C, 23B and 22F. (Tables 2 and 3 ). In general, macrolides were rarely recently prescribed with the exception of 48 of 396 (13%) children the Darwin Rural region (Table 3) . Of these 48 children, 45 were from one community and had been prescribed azithromycin for trachoma eradication.
Antibiotic resistance
Carriage of penicillin non-susceptible pneumococci (MIC ≥ 0.12 μg/mL) was 17% in 2003 and 14% in 2005 (Table   2 ). In Central Australia where prescribing was highest, carriage was 25% in 2003 and 42% in 2005 (Table 3) . Penicillin resistance of 1.0 μg/mL or more was found in six children from 3 communities, all were serotype 9 V. Azithromycin resistant pneumococci (MIC ≥ 2 μg/mL) were 
Antibiotic-resistant serotypes
Penicillin resistance (MIC> = 0.12 μg/mL) was found in both 7PCV and non-7PCV serotypes (Figure 2 Macrolide resistance (azithromycin MIC ≥ 2 μg/mL) was found mainly in the non-7PCV serotypes (Figure 2 ). Eight
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Discussion
Our survey of 1720 young children in remote communities two and four years after commencement of a government funded schedule for Indigenous children of 7PCV at 2, 4 and 6 months followed by a booster 23PPV at 18 months of age, provides a valuable source of pneumococcal serotype and susceptibility data for the region. Two major influences have had the potential to impact on pneumococcal carriage in this population; pneumococcal vaccination and antimicrobial prescribing. In three communities studied extensively in the 1990s, around 50% children carried 7PCV serotypes. Predominant pre-7PCV serotypes were 6B, 19F, 23F, 19A, 16F and 6A (unpublished data from 3 of the communities also in these surveys). Retrospective PCR analysis confirms one of 20 pre-7PCV 6A isolates was 6C. [15] A similar serotype distribution was found in cultures of discharge from acute perforations of the tympanic membrane. [16] In This trend was consistent across all age groups. Similarly for 7PCV types (-4%). There was a small reduction in 6A. Overall, carriage of 23PPV-non-7PCV types was significantly reduced (-5%), including serotype 19A (-4%), but other 23PPV-non-7PCV types (20 and 9N) increased. Non-vaccine serotypes (not in 23PPV) increased by 10%, mainly attributable to serotypes 23B, 34 and 10F. Serotypes 6C and 16F remained unchanged.
Among the group of children not vaccinated, 19A, 16F and 6A and 6C were the predominant serotypes and 7PCV type carriage was less than 10%, indicating a herd effect. Similarly, in very young non-vaccinated infants (mean age 1.9 months) carriage was around 58% and only 8% carried 7PCV vaccine types. Serotypes were diverse and no dominant emerging serotype was evident in this young group.
There is no strong evidence from 23PPV studies to suggest that 23PPV has an impact on NP carriage [17] Our immunogenicity study [18] showed 23PPV to be an effective booster for 7PCV-primed serotypes, and that modest responses to some additional serotypes in 23PPV also occurred. Whether the antibody concentrations achieved would prevent pneumococcal acquisition in the nasopharynx was not assessed. In this survey we did detect [-5, 18] ). Our previous longitudinal study [19] had shown that azithromycin reduces carriage of pneumococci, providing resistant strains with a selective advantage that allows spread within the community. Over time, and in the absence of further azithromycin use or selective pressure, susceptible stains re-populate and the proportion of the population carrying resistant strains declines. [19] The present cross-sectional study does not capture this dynamic process and therefore does not allow any conclusions regarding the relationship between mass azithromycin use and carriage. In Central Australia, recent macrolide prescribing was rare, but carriage of azithromycin resistant strains was clearly higher than other regions. We suggest that this higher background of resistance may be related to a longer period of exposure to azithromycin for trachoma [20] and STI (sexually transmitted infection) [21] Reporting of pneumococcal epidemiology needs to consider the epidemic and endemic nature of various serotypes and that serotype-specific data are needed to best describe and prepare for shifts over time and in response to vaccines and antibiotic selective pressures.
Otitis media (OM) serotypes closely align with carriage serotype profile, [23] and for Aboriginal children OM is a common and serious infection often resulting in chronic suppurative OM (CSOM). This study showed that the serotypes colonising infants at 2 months of age, and therefore the serotypes most likely causing early OM, [24] are no longer 7PCV-types. Vaccines that are effective in preventing early onset of ear disease (and pneumonia) are urgently needed.
Conclusion
Pneumococcal disease epidemiology is in a transition period in Australia. This surveillance shows that nasal carriage of 7PCV serotypes has been replaced by the serotypes that were the next most common carriage serotypes prior to 7PCV use -namely 19A and 16F. Antibiotic resistance is almost exclusively restricted to these serotypes (and remaining 7PCV serotypes) and requires monitoring at the regional level. The role of 23PPV in limiting carriage and preventing disease in children also needs further investigation. More work is needed to guide design of appropriate surveillance systems that measure serotype shifts and distinguish serotype replacement from secular trends.
